What treatment should be given for multiple sclerosis at the present time?

被引:1
|
作者
Ramo-Tello, C [1 ]
León-Colombo, T [1 ]
机构
[1] Hosp Princesa, Serv Neurol, E-28006 Madrid, Spain
关键词
corticosteroids; interferons; multiple sclerosis; treatment;
D O I
10.33588/rn.3010.99372
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective. This communication aims to describe an approach suitable for the general neurologist or neurologist specialized in treating other disorders, to the current treatment of multiple sclerosis. Development and conclusions. We discuss the treatments for recovery from the symptoms of an acute attack and those which modify the natural course of the illness (reduce the frequency and severity of attacks and/or prevent their progression). The attacks are treated with corticosteroids or ACTH Both treatments have been shown on clinical trials to cause rapid improvement of the acute symptoms of an attack. In the progressive forms, the usefulness of high closes of corticosteroids has not been shown. Nor is there evidence that long term corticosteroid treatment, either daily or monthly, is of use in reducing the number of attacks or progression of the disease, although serious side-effects have been seen. At the moment, the interferons are the most popular treatment for multiple sclerosis. They have been the first drugs to modify the course of the disorder. Finally we describe some of the most generally used treatments and some under investigation, although they ave not widely used since it is still not clear exactly how they affect the course of the disease.
引用
收藏
页码:993 / 995
页数:3
相关论文
共 50 条
  • [41] Exercising in pregnancy: what advice should be given to patients?
    Woodman, Sarah
    Reina-Fernandez, Jordana
    Goldberg, Jay
    WOMENS HEALTH, 2014, 10 (06) : 547 - 548
  • [43] What role should spinal cord MRI take in the future of multiple sclerosis surveillance?
    Rocca, Maria A.
    Preziosa, Paolo
    Filippi, Massimo
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2020, 20 (08) : 783 - 797
  • [44] Protected clinical support time should be a given: No
    Herrmann, Anna
    EMERGENCY MEDICINE AUSTRALASIA, 2018, 30 (04) : 571 - 572
  • [45] Matrix metalloproteinases in multiple sclerosis: Is it time for a treatment trial?
    Rosenberg, GA
    ANNALS OF NEUROLOGY, 2001, 50 (04) : 431 - 433
  • [46] Highly Effective Therapy Versus Escalation Approaches in Early Multiple Sclerosis What Is the Future of Multiple Sclerosis Treatment?
    Rjeily, Nicole Bou
    Mowry, Ellen M.
    Ontaneda, Daniel
    Carlson, Alise K.
    NEUROLOGIC CLINICS, 2024, 42 (01) : 185 - 201
  • [47] MULTIPLE-SCLEROSIS - THE PRESENT POSITION
    MCDONALD, WI
    ACTA NEUROLOGICA SCANDINAVICA, 1983, 68 (02): : 65 - 76
  • [48] Immunopathogenesis of multiple sclerosis: past and present
    Kieseier, B. C.
    JOURNAL OF NEURAL TRANSMISSION, 2007, 114 (07) : CIV - CV
  • [49] Present and future of fMRI in multiple sclerosis
    Filippi, Massimo
    Rocca, Maria A.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (12) : 27 - 31
  • [50] Should neutralizing antibodies be monitored during interferon-β treatment for multiple sclerosis?
    Oger, J
    Gibbs, E
    NATURE CLINICAL PRACTICE NEUROLOGY, 2006, 2 (02): : 76 - 77